• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

健康和患病人类肾脏中膜攻击复合物的沉积。

Deposition of the Membrane Attack Complex in Healthy and Diseased Human Kidneys.

机构信息

Division of Renal Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.

Division of Nephrology, Department of Internal Medicine, Leiden University Medical Center, Leiden, Netherlands.

出版信息

Front Immunol. 2021 Feb 11;11:599974. doi: 10.3389/fimmu.2020.599974. eCollection 2020.

DOI:10.3389/fimmu.2020.599974
PMID:33643288
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7906018/
Abstract

The membrane attack complex-also known as C5b-9-is the end-product of the classical, lectin, and alternative complement pathways. It is thought to play an important role in the pathogenesis of various kidney diseases by causing cellular injury and tissue inflammation, resulting in sclerosis and fibrosis. These deleterious effects are, consequently, targeted in the development of novel therapies that inhibit the formation of C5b-9, such as eculizumab. To clarify how C5b-9 contributes to kidney disease and to predict which patients benefit from such therapy, knowledge on deposition of C5b-9 in the kidney is essential. Because immunohistochemical staining of C5b-9 has not been routinely conducted and never been compared across studies, we provide a review of studies on deposition of C5b-9 in healthy and diseased human kidneys. We describe techniques to stain deposits and compare the occurrence of deposits in healthy kidneys and in a wide spectrum of kidney diseases, including hypertensive nephropathy, diabetic nephropathy, membranous nephropathy, IgA nephropathy, lupus nephritis, C3 glomerulopathy, and thrombotic microangiopathies such as the atypical hemolytic uremic syndrome, vasculitis, interstitial nephritis, acute tubular necrosis, kidney tumors, and rejection of kidney transplants. We summarize how these deposits are related with other histological lesions and clinical characteristics. We evaluate the prognostic relevance of these deposits in the light of possible treatment with complement inhibitors.

摘要

膜攻击复合物-也称为 C5b-9-是经典途径、凝集素途径和替代途径的终产物。它被认为通过引起细胞损伤和组织炎症,导致硬化和纤维化,在各种肾脏疾病的发病机制中发挥重要作用。因此,在开发抑制 C5b-9 形成的新型疗法(如依库珠单抗)时,针对这些有害作用。为了阐明 C5b-9 如何导致肾脏疾病,并预测哪些患者受益于这种治疗,了解 C5b-9 在肾脏中的沉积至关重要。由于 C5b-9 的免疫组织化学染色未常规进行,并且从未在研究之间进行比较,因此我们提供了对健康和患病人类肾脏中 C5b-9 沉积的研究综述。我们描述了染色沉积物的技术,并比较了健康肾脏和广泛的肾脏疾病(包括高血压性肾病、糖尿病肾病、膜性肾病、IgA 肾病、狼疮肾炎、C3 肾小球病和血栓性微血管病,如非典型溶血性尿毒症综合征、血管炎、间质性肾炎、急性肾小管坏死、肾肿瘤和肾移植排斥)中沉积物的发生。我们总结了这些沉积物与其他组织学病变和临床特征的关系。我们根据可能使用补体抑制剂治疗的情况,评估了这些沉积物的预后相关性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/368b/7906018/38fcc5059a59/fimmu-11-599974-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/368b/7906018/5c997ba3f2cf/fimmu-11-599974-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/368b/7906018/a7d1d576c192/fimmu-11-599974-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/368b/7906018/7cad3354a9a8/fimmu-11-599974-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/368b/7906018/6a2ffb890e97/fimmu-11-599974-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/368b/7906018/c0e3468a6a4e/fimmu-11-599974-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/368b/7906018/4cc6786ec047/fimmu-11-599974-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/368b/7906018/54b86032e058/fimmu-11-599974-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/368b/7906018/220e48a77fe8/fimmu-11-599974-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/368b/7906018/38fcc5059a59/fimmu-11-599974-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/368b/7906018/5c997ba3f2cf/fimmu-11-599974-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/368b/7906018/a7d1d576c192/fimmu-11-599974-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/368b/7906018/7cad3354a9a8/fimmu-11-599974-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/368b/7906018/6a2ffb890e97/fimmu-11-599974-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/368b/7906018/c0e3468a6a4e/fimmu-11-599974-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/368b/7906018/4cc6786ec047/fimmu-11-599974-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/368b/7906018/54b86032e058/fimmu-11-599974-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/368b/7906018/220e48a77fe8/fimmu-11-599974-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/368b/7906018/38fcc5059a59/fimmu-11-599974-g009.jpg

相似文献

1
Deposition of the Membrane Attack Complex in Healthy and Diseased Human Kidneys.健康和患病人类肾脏中膜攻击复合物的沉积。
Front Immunol. 2021 Feb 11;11:599974. doi: 10.3389/fimmu.2020.599974. eCollection 2020.
2
Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway.罕见炎症性肾病的治疗:靶向末端补体途径的药物。
Front Immunol. 2020 Dec 10;11:599417. doi: 10.3389/fimmu.2020.599417. eCollection 2020.
3
Immunohistochemical study of the C5b-9 complex of complement in human kidneys.人肾补体C5b - 9复合物的免疫组织化学研究
Kidney Int. 1986 Sep;30(3):399-410. doi: 10.1038/ki.1986.198.
4
An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome.在体外对补体激活进行测试,为溶血尿毒综合征的依库珠单抗个体化治疗提供依据。
Am J Kidney Dis. 2019 Jul;74(1):56-72. doi: 10.1053/j.ajkd.2018.11.012. Epub 2019 Mar 7.
5
Immunohistochemical study of complement S protein (Vitronectin) in normal and diseased human kidneys: relationship to neoantigens of the C5b-9 terminal complex.正常和患病人类肾脏中补体S蛋白(玻连蛋白)的免疫组织化学研究:与C5b-9末端复合物新抗原的关系
Clin Exp Immunol. 1989 Jan;75(1):76-81.
6
Complement-mediated microangiopathy in IgA nephropathy and IgA vasculitis with nephritis.补体介导的 IgA 肾病和 IgA 血管炎伴肾炎的微血管病。
Mod Pathol. 2019 Jul;32(8):1147-1157. doi: 10.1038/s41379-019-0259-z. Epub 2019 Apr 1.
7
Measurement of Complement Activation via Plasma-Soluble C5b-9 Comparison with Terminal Complement Complex Staining in a Series of Kidney Biopsies.通过血浆可溶性 C5b-9 测量补体激活与一系列肾活检中的末端补体复合物染色比较。
Kidney Blood Press Res. 2023;48(1):220-230. doi: 10.1159/000529734. Epub 2023 Mar 14.
8
Eculizumab deposits in vessel walls in thrombotic microangiopathy.依库珠单抗在血栓性微血管病的血管壁中沉积。
Kidney Int. 2019 Sep;96(3):761-768. doi: 10.1016/j.kint.2019.05.008. Epub 2019 May 24.
9
C5b-9 and adhesion molecules in human idiopathic membranous nephropathy.C5b-9与人类特发性膜性肾病中的黏附分子
Nephrol Dial Transplant. 2002 Jan;17(1):57-63. doi: 10.1093/ndt/17.1.57.
10
Complement Activation and Thrombotic Microangiopathies.补体激活与血栓性微血管病。
Clin J Am Soc Nephrol. 2019 Dec 6;14(12):1719-1732. doi: 10.2215/CJN.05830519. Epub 2019 Nov 6.

引用本文的文献

1
C-reactive protein dissociation drives choroidal neovascularization in age-related macular degeneration.C反应蛋白解离驱动年龄相关性黄斑变性中的脉络膜新生血管形成。
Sci Rep. 2025 Aug 26;15(1):31408. doi: 10.1038/s41598-025-16631-z.
2
Complement Activation is More Pronounced in the Kidneys of Critically Ill Patients With COVID-19 Than in Those With Bacterial Sepsis.与细菌性脓毒症患者相比,新冠重症患者肾脏中的补体激活更为明显。
Kidney Int Rep. 2025 Apr 21;10(7):2284-2295. doi: 10.1016/j.ekir.2025.04.027. eCollection 2025 Jul.
3
Complement Inhibition Therapy in IgA Nephropathy: Total or Selective Inhibition?

本文引用的文献

1
Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection.人类肾脏是新型严重急性呼吸综合征冠状病毒 2 感染的靶器官。
Nat Commun. 2021 May 4;12(1):2506. doi: 10.1038/s41467-021-22781-1.
2
Complement activation is a crucial driver of acute kidney injury in rhabdomyolysis.补体激活是横纹肌溶解症中急性肾损伤的关键驱动因素。
Kidney Int. 2021 Mar;99(3):581-597. doi: 10.1016/j.kint.2020.09.033. Epub 2020 Nov 1.
3
Clinical Use of Complement, Inflammation, and Fibrosis Biomarkers in Autoimmune Glomerulonephritis.
IgA肾病中的补体抑制疗法:全面抑制还是选择性抑制?
J Am Soc Nephrol. 2025 May 1;36(5):984-985. doi: 10.1681/ASN.0000000673. Epub 2025 Mar 26.
4
Claudin-2 enhances human antibody-mediated complement-dependent cytotoxicity of porcine endothelial cells by modulating antibody binding and complement activation.Claudin-2通过调节抗体结合和补体激活增强人抗体介导的猪内皮细胞补体依赖性细胞毒性。
Front Immunol. 2025 Feb 18;16:1547512. doi: 10.3389/fimmu.2025.1547512. eCollection 2025.
5
Urine Complement Factor Ba Identifies Persistent Acute Kidney Injury and Organ Failures in Critically Ill Adults.尿补体因子Ba可识别危重症成年患者的持续性急性肾损伤和器官功能衰竭。
Kidney Int Rep. 2024 Nov 25;10(2):424-431. doi: 10.1016/j.ekir.2024.11.030. eCollection 2025 Feb.
6
Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial.ravulizumab治疗IgA肾病的疗效与安全性:一项2期随机双盲安慰剂对照试验
J Am Soc Nephrol. 2025 Apr 1;36(4):645-656. doi: 10.1681/ASN.0000000534. Epub 2024 Oct 25.
7
The pathogenesis of IgA nephropathy and implications for treatment.IgA肾病的发病机制及其治疗意义。
Nat Rev Nephrol. 2025 Jan;21(1):9-23. doi: 10.1038/s41581-024-00885-3. Epub 2024 Sep 4.
8
Apical tubular complement activation and the loss of kidney function in proteinuric kidney diseases.顶端肾小管补体激活与蛋白尿性肾脏疾病中的肾功能丧失
Clin Kidney J. 2024 Jul 10;17(8):sfae215. doi: 10.1093/ckj/sfae215. eCollection 2024 Aug.
9
Complement Membrane Attack Complexes Disrupt Proteostasis to Function as Intracellular Alarmins.补体膜攻击复合物破坏蛋白质稳态,作为细胞内警报素发挥作用。
Res Sq. 2024 Jun 19:rs.3.rs-4504419. doi: 10.21203/rs.3.rs-4504419/v1.
10
Urinary complement biomarkers in immune-mediated kidney diseases.免疫介导性肾脏疾病中的尿液补体生物标志物。
Front Immunol. 2024 Jun 3;15:1357869. doi: 10.3389/fimmu.2024.1357869. eCollection 2024.
补体、炎症和纤维化生物标志物在自身免疫性肾小球肾炎中的临床应用
Kidney Int Rep. 2020 Jul 23;5(10):1690-1699. doi: 10.1016/j.ekir.2020.07.018. eCollection 2020 Oct.
4
PTX3 modulates the immunoflogosis in tumor microenvironment and is a prognostic factor for patients with clear cell renal cell carcinoma.PTX3 调节肿瘤微环境中的免疫炎症反应,是透明细胞肾细胞癌患者的预后因素。
Aging (Albany NY). 2020 Apr 28;12(8):7585-7602. doi: 10.18632/aging.103169.
5
Complement activation is associated with crescent formation in IgA nephropathy.补体激活与 IgA 肾病中新月体的形成有关。
Virchows Arch. 2020 Oct;477(4):565-572. doi: 10.1007/s00428-020-02800-0. Epub 2020 Apr 16.
6
Complement Membrane Attack Complex: New Roles, Mechanisms of Action, and Therapeutic Targets.补体膜攻击复合物:新的作用、作用机制和治疗靶点。
Am J Pathol. 2020 Jun;190(6):1138-1150. doi: 10.1016/j.ajpath.2020.02.006. Epub 2020 Mar 16.
7
Morphofunctional Effects of C5 Convertase Blockade in Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Report of Two Cases with Evidence of Terminal Complement Activation.免疫复合物介导的膜增殖性肾小球肾炎中 C5 转化酶阻断的形态功能效应:伴有末端补体激活证据的两例报告。
Nephron. 2020;144(4):195-203. doi: 10.1159/000505403. Epub 2020 Feb 12.
8
Dysregulation of Complement Activation and Placental Dysfunction: A Potential Target to Treat Preeclampsia?补体激活失调与胎盘功能障碍:子痫前期治疗的新靶点?
Front Immunol. 2020 Jan 15;10:3098. doi: 10.3389/fimmu.2019.03098. eCollection 2019.
9
Clinical relevance of membrane attack complex deposition in children with IgA nephropathy and Henoch-Schönlein purpura.膜攻击复合物在儿童 IgA 肾病和过敏性紫癜中的沉积的临床意义。
Pediatr Nephrol. 2020 May;35(5):843-850. doi: 10.1007/s00467-019-04445-x. Epub 2020 Jan 13.
10
Complement and Complement Targeting Therapies in Glomerular Diseases.补体系统及肾小球疾病的补体靶向治疗。
Int J Mol Sci. 2019 Dec 16;20(24):6336. doi: 10.3390/ijms20246336.